Incidence of treatment for end-stage renal disease among individuals with diabetes in the U.S. continues to decline: response to Burrows, Li, and Geiss.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

1. The Incidence of End-Stage Renal Disease in the Diabetic (Compared to the Non-Diabetic) Population: A Systematic Review.PloS one · 2016
   Pooled it
2. Incidence and relative risk of renal replacement therapy in people with and without diabetes between 2002 and 2016 in a German region.Diabetologia · 2020
   Article

Corrections and comments

• Comment on
  Incidence of treatment for end-stage renal disease among individuals with diabetes in the U.S. continues to decline.2010

Authors and funding

3 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as